PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BCAB vs. OCEA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between BCAB and OCEA is 0.07, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

BCAB vs. OCEA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioAtla, Inc. (BCAB) and Ocean Biomedical Inc. (OCEA). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%SeptemberOctoberNovemberDecember2025February
-75.24%
-87.58%
BCAB
OCEA

Key characteristics

Sharpe Ratio

BCAB:

-0.67

OCEA:

-0.31

Sortino Ratio

BCAB:

-1.16

OCEA:

0.48

Omega Ratio

BCAB:

0.86

OCEA:

1.05

Calmar Ratio

BCAB:

-0.82

OCEA:

-0.79

Martin Ratio

BCAB:

-1.46

OCEA:

-1.02

Ulcer Index

BCAB:

55.98%

OCEA:

76.54%

Daily Std Dev

BCAB:

121.92%

OCEA:

249.66%

Max Drawdown

BCAB:

-99.46%

OCEA:

-99.02%

Current Drawdown

BCAB:

-99.34%

OCEA:

-98.99%

Fundamentals

Market Cap

BCAB:

$27.18M

OCEA:

$25.64M

EPS

BCAB:

-$1.70

OCEA:

-$3.00

Total Revenue (TTM)

BCAB:

$11.00M

OCEA:

$0.00

EBITDA (TTM)

BCAB:

-$57.23M

OCEA:

-$8.15M

Returns By Period

In the year-to-date period, BCAB achieves a -20.75% return, which is significantly higher than OCEA's -76.17% return.


BCAB

YTD

-20.75%

1M

-4.97%

6M

-75.21%

1Y

-79.27%

5Y*

N/A

10Y*

N/A

OCEA

YTD

-76.17%

1M

-75.59%

6M

-87.56%

1Y

-75.73%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

BCAB vs. OCEA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BCAB
The Risk-Adjusted Performance Rank of BCAB is 88
Overall Rank
The Sharpe Ratio Rank of BCAB is 1212
Sharpe Ratio Rank
The Sortino Ratio Rank of BCAB is 88
Sortino Ratio Rank
The Omega Ratio Rank of BCAB is 1010
Omega Ratio Rank
The Calmar Ratio Rank of BCAB is 44
Calmar Ratio Rank
The Martin Ratio Rank of BCAB is 66
Martin Ratio Rank

OCEA
The Risk-Adjusted Performance Rank of OCEA is 2828
Overall Rank
The Sharpe Ratio Rank of OCEA is 2828
Sharpe Ratio Rank
The Sortino Ratio Rank of OCEA is 4343
Sortino Ratio Rank
The Omega Ratio Rank of OCEA is 4141
Omega Ratio Rank
The Calmar Ratio Rank of OCEA is 55
Calmar Ratio Rank
The Martin Ratio Rank of OCEA is 2121
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BCAB vs. OCEA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for BioAtla, Inc. (BCAB) and Ocean Biomedical Inc. (OCEA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for BCAB, currently valued at -0.67, compared to the broader market-2.000.002.004.00-0.67-0.31
The chart of Sortino ratio for BCAB, currently valued at -1.16, compared to the broader market-6.00-4.00-2.000.002.004.006.00-1.160.48
The chart of Omega ratio for BCAB, currently valued at 0.86, compared to the broader market0.501.001.502.000.861.05
The chart of Calmar ratio for BCAB, currently valued at -0.83, compared to the broader market0.002.004.006.00-0.83-0.79
The chart of Martin ratio for BCAB, currently valued at -1.46, compared to the broader market0.0010.0020.0030.00-1.46-1.02
BCAB
OCEA

The current BCAB Sharpe Ratio is -0.67, which is lower than the OCEA Sharpe Ratio of -0.31. The chart below compares the historical Sharpe Ratios of BCAB and OCEA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.60-0.40-0.200.000.200.40SeptemberOctoberNovemberDecember2025February
-0.67
-0.31
BCAB
OCEA

Dividends

BCAB vs. OCEA - Dividend Comparison

Neither BCAB nor OCEA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BCAB vs. OCEA - Drawdown Comparison

The maximum BCAB drawdown since its inception was -99.46%, roughly equal to the maximum OCEA drawdown of -99.02%. Use the drawdown chart below to compare losses from any high point for BCAB and OCEA. For additional features, visit the drawdowns tool.


-100.00%-98.00%-96.00%-94.00%-92.00%SeptemberOctoberNovemberDecember2025February
-98.43%
-98.99%
BCAB
OCEA

Volatility

BCAB vs. OCEA - Volatility Comparison

The current volatility for BioAtla, Inc. (BCAB) is 24.12%, while Ocean Biomedical Inc. (OCEA) has a volatility of 58.60%. This indicates that BCAB experiences smaller price fluctuations and is considered to be less risky than OCEA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
24.12%
58.60%
BCAB
OCEA

Financials

BCAB vs. OCEA - Financials Comparison

This section allows you to compare key financial metrics between BioAtla, Inc. and Ocean Biomedical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab